Mod GRF 1-29 vs P21
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →P21
P21 is a synthetic peptide derived from Cerebrolysin, specifically designed to mimic the neurotrophic effects of the parent compound. It promotes neurogenesis and has shown cognitive-enhancing properties in research.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | P21 |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Inhibits glycogen synthase kinase-3β (GSK-3β) and activates CREB signaling pathway. This promotes BDNF expression, neurogenesis in the hippocampus, and synaptic plasticity. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Research protocols typically use 1-5mg administered intranasally or subcutaneously. Often used in cycles of 2-4 weeks. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Can be administered intranasally for direct CNS access or subcutaneously. Best used cyclically rather than continuously. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Limited data. Reported effects include mild headache, temporary brain fog during initial use, and fatigue. |
| Best For |